Accutar Biotechnology Announces FDA Clearance of IND Application for Phase 1 Trial of AC0176 in Prostate Cancer
BROOKLYN, N.Y.--(BUSINESS WIRE)--Accutar Biotechnology, Inc., a biotechnology company focusing on artificial intelligence (AI)-empowered drug discovery, today announced that the U.S....






